H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C. Wainwright analyst Joseph Pantginis maintained a buy rating and $42 price target on Edgewise Therapeutics, Inc. (NASDAQ:EWTX) on October 13, supporting the optimistic rating with the company’s promising developments in the treatment of Becker muscular dystrophy (BMD).

The analyst stated that Edgewise Therapeutics, Inc.’s (NASDAQ:EWTX) investigational drug, sevasemten, is highlighted as a potential first-in-class therapy to prevent muscle damage in BMD patients. The condition does not have any currently approved treatments, and the drug’s progress, which was highlighted at the 2025 International Annual Congress of the World Muscle Society, reflects its potential to address the unmet needs for BMD.

Therefore, sevasemten’s promising clinical results, especially in improving functional outcomes, support the analyst’s bullish outlook for Edgewise Therapeutics, Inc. (NASDAQ:EWTX).

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company that develops, discovers, and commercializes innovative treatments for serious, rare muscle disorders with considerable unmet medical needs and severe cardiac conditions. Its lead product candidate is sevasemten (EDG-5506), an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies.

While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.